The primary asset of that "whole company" was Dapt
Post# of 72436
![](/assets/46931549/no_avatar_available_thumb.jpg)
It is a fact that Merck paid $9.5 billion for a company who's most valuable asset (by far) was Daptomycin.
Quote:
"Go read the post I am replying to; I'm not the one who brought up Trius acquisition. You're wrong that Cubist sold Cubicin to Merck for $9B. It was the whole company that was acquired and it's not just Cubicin that was sold. There were other antibiotics that were inherited from that acquisition and that includes Zerbaxa and Sivextro (originally from Trius), hence that's why the whole acquisition was worth $9B." - lousy engineer
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)